Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 4 | 5 |
List of Tables | 6 | 1 |
List of Figures | 6 | 3 |
Introduction | 9 | 14 |
Therapy Area Introduction | 9 | 1 |
Symptoms | 10 | 1 |
Gastroesophageal Reflux Disease | 10 | 1 |
Irritable Bowel Syndrome | 10 | 1 |
Inflammatory Bowel Disease | 10 | 1 |
Etiology and Pathophysiology | 11 | 1 |
Gastroesophageal Reflux Disease | 11 | 1 |
Irritable Bowel Syndrome | 12 | 2 |
Inflammatory Bowel Disease | 14 | 1 |
Co-morbidities and Complications | 15 | 1 |
Epidemiology Patterns and Forecasts Prevalence and Patient Segmentation | 16 | 1 |
Gastroesophageal Reflux Disease | 17 | 1 |
Irritable Bowel Syndrome | 17 | 1 |
Inflammatory Bowel Disease | 18 | 1 |
Treatment | 19 | 1 |
Acid-Controlling Agents | 19 | 1 |
Antacids | 19 | 1 |
Histamine-2 Receptor Antagonist | 19 | 1 |
Proton Pump Inhibitors | 19 | 1 |
Anticholinergics/Antispasmodics | 20 | 1 |
Gastric Stimulants, Laxatives and Antidiarrheals | 20 | 1 |
Anti-inflammatory and Systemic Immunosuppressive Agents | 21 | 1 |
Aminosalicylates | 21 | 1 |
Immunomodulators | 21 | 1 |
Corticosteroids | 21 | 1 |
Biologics | 22 | 1 |
Key Marketed Products | 23 | 22 |
Overview | 23 | 1 |
Humira (adalimumab) | 24 | 2 |
Remicade (infliximab) | 26 | 2 |
Soliris (eculizumab) | 28 | 1 |
Tysabri (natalizumab) | 29 | 2 |
Nexium (esomeprazole magnesium) | 31 | 2 |
Entyvio (vedolizumab) | 33 | 2 |
Protonix (pantoprazole) | 35 | 2 |
Ocaliva (obeticholic acid) | 37 | 1 |
Dexilant (dexlansoprazole) | 38 | 2 |
Amitiza (lubiprostone) | 40 | 1 |
Takecab (vonoprazan) | 41 | 2 |
Linzess (linaclotide) | 43 | 2 |
Pipeline Landscape Assessment | 45 | 27 |
Overview | 45 | 2 |
Molecule Types in the Pipeline | 47 | 1 |
Molecular Targets in the Pipeline | 48 | 2 |
Clinical Trials Landscape | 50 | 1 |
Clinical Trial Failure Rates | 51 | 1 |
Clinical Trial Failure Rates by Stage of Development | 51 | 1 |
Clinical Trial Failure Rates by Indication | 51 | 1 |
Clinical Trial Failure Rates by Molecule Type | 52 | 1 |
Clinical Trial Failure Rates by Molecular Target | 53 | 1 |
Clinical Trial Duration | 54 | 1 |
Clinical Trial Duration by Stage of Development | 54 | 1 |
Clinical Trial Duration by Indication and Stage of Development | 55 | 1 |
Clinical Trial Duration by Molecule Type and Stage of Development | 56 | 1 |
Clinical Trial Duration by Molecular Target and Stage of Development | 57 | 1 |
Clinical Trial Size | 58 | 1 |
Clinical Trial Size by Stage of Development | 58 | 1 |
Clinical Trial Size by Indication and Stage of Development | 59 | 1 |
Clinical Trial Size by Molecule Type and Stage of Development | 60 | 1 |
Clinical Trial Size by Molecular Target and Stage of Development | 60 | 1 |
Cumulative Clinical Trial Size | 61 | 1 |
Indication, Molecule Type and Molecular Target | 62 | 2 |
Late-Stage Drugs of the Developmental Pipeline | 64 | 1 |
RPC1063 (ozanimod) Celgene | 64 | 1 |
Drug Forecast | 65 | 1 |
GED-0301 (mongersen) Celgene | 65 | 1 |
Drug Forecast | 66 | 1 |
Stelara (ustekinumab) Johnson &Johnson | 66 | 1 |
Drug Forecast | 67 | 1 |
Victoza (liraglutide) Novo Nordisk | 68 | 1 |
Drug Forecast | 69 | 1 |
Plecanatide Synergy Pharmaceuticals | 69 | 1 |
Drug Forecast | 70 | 1 |
Conclusion | 70 | 2 |
Multi-scenario Market Forecast to 2022 | 72 | 8 |
Overall Market Size | 72 | 2 |
Generic Penetration | 74 | 1 |
Revenue Forecast by Molecular Target | 75 | 1 |
Tumor Necrosis Factor Alpha | 75 | 1 |
Interleukins and Receptors | 76 | 1 |
H+/K+ ATPase | 77 | 1 |
Integrins | 78 | 2 |
Company Analysis and Positioning | 80 | 19 |
Revenue and Market Share Analysis by Company | 81 | 4 |
AbbVie Will Patent Expiry of Humira Significantly Diminish Revenues? | 85 | 2 |
Takeda Will Entyvio and Takecab be the Predominant Contributors to Revenue Growth? | 87 | 1 |
Johnson &Johnson To What Extent Will Simponi Offset the Patent Expiry of Remicade? | 88 | 2 |
AstraZeneca 0T 0TWill Patent Expiration of Blockbuster Drug and Lack of Strong Pipeline Line-up Result in Loss of Market Share? | 90 | 2 |
Alexion Is Soliris Success Enough to Drive Strong Company Growth? | 92 | 1 |
Allergan To What Extent Will Key Gastrointestinal Product Linzess Drive Company Growth? | 93 | 2 |
Celgene Which Gastrointestinal Pipeline Drugs Will Drive Growth in Second Half of Forecast Period? | 95 | 1 |
Company Landscape | 96 | 1 |
Marketed and Pipeline Portfolio Analysis | 96 | 3 |
Strategic Consolidations | 99 | 12 |
Licensing Deals | 99 | 1 |
Deals by Region, Year and Value | 99 | 2 |
Deals by Stage of Development and Value | 101 | 1 |
Deals by Molecule Type, Molecular Target and Value | 102 | 2 |
Table for Licensing Deals Valued Above $300m | 104 | 1 |
Co-development Deals | 105 | 1 |
Deals by Region, Year and Value | 105 | 1 |
Deals by Stage of Development and Value | 106 | 2 |
Deals by Molecule Type, Molecular Target and Value | 108 | 1 |
Table for Co-development Deals Valued Above $300m | 109 | 2 |
Appendix | 111 | 51 |
References | 111 | 4 |
Table of Epidemiology Forecast | 115 | 1 |
Table of All Clinical Stage Pipeline Products | 116 | 41 |
Abbreviations | 157 | 1 |
Disease List | 158 | 1 |
Methodology | 159 | 2 |
Coverage | 159 | 1 |
Secondary Research | 159 | 1 |
Market Size and Revenue Forecasts | 159 | 1 |
Pipeline Analysis | 160 | 1 |
Competitive Landscape | 160 | 1 |
Contact Us | 161 | 1 |
Disclaimer | 161 | 1 |